AnaptysBio Q2 collaboration revenue doubles

AnaptysBio

06/08/2025 22:53

Overview

AnaptysBio Q2 collaboration revenue more than doubles year-over-year

Net loss narrows to $38.6 mln from $46.7 mln in prior year

Co repurchased 9.3% of shares, reflecting confidence in financial position

Result Drivers

ROSNILIMAB DATA - Positive Phase 2b trial results for rosnilimab in rheumatoid arthritis with strong safety and efficacy profile

ULCERATIVE COLITIS TRIAL - Completed enrollment for Phase 2 trial with top-line data expected in Q4 2025

PIPELINE ADVANCEMENT - Ongoing Phase 1 trials for ANB033 and ANB101, with plans for a Phase 1b cohort for ANB033 in celiac disease

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
$22.26 mln
Q2 EPS
-$1.34
Q2 Net Income
-$38.63 mln
Q2 Income From Operations
-$26.17 mln
Q2 Operating Expenses
$48.43 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for AnaptysBio Inc is $45.50, about 47.9% above its August 5 closing price of $23.69

Press Release: ID:nGNX8G2DQs

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)